OncoMatch/Clinical Trials/NCT04447352
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Is NCT04447352 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for gastric cancer.
Treatment: 5-Fluorouracil · Leucovorin · Oxaliplatin · Docetaxel · Cisplatin — This is a multicenter, randomized, controlled, open-label study evaluating efficacy and safety of perioperative FLOT chemotherapy plus intraoperative HIPEC versus FLOT chemotherapy alone in patients with resectable localized and locally advanced diffuse and mixed type adenocarcinoma of the stomach and Type II/III GEJ.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Disease stage
Required: Stage UT3, UT4A, ANY T N+ M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: FLOT chemotherapy (5-FU, leucovorin, oxaliplatin, docetaxel) — neoadjuvant
Patient has received 3 to 6 cycles of neoadjuvant FLOT (de-escalation or dose modification allowed)
Cannot have received: cytotoxic or targeted therapy
Exception: other than neoadjuvant FLOT (including de-escalated or dose reduced schema) therapy
No preceding cytotoxic or targeted therapy other than neoadjuvant FLOT (including de-escalated or dose reduced schema) therapy
Cannot have received: tumor resection
No prior partial or complete tumor resection
Lab requirements
Blood counts
adequate to allow surgical procedure and hipec at investigator´s discretion
Kidney function
adequate to allow surgical procedure and hipec at investigator´s discretion
Liver function
adequate to allow surgical procedure and hipec at investigator´s discretion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04447352 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic or targeted therapy, tumor resection disqualifies patients from enrollment.
What disease stage is eligible?
Stage UT3 or UT4A or ANY T N+ M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages